BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys 2020;7:41. [PMID: 32556844 DOI: 10.1186/s40658-020-00311-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kurth J, Heuschkel M, Tonn A, Schildt A, Hakenberg OW, Krause BJ, Schwarzenböck SM. Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer. Cancers (Basel) 2021;13:3884. [PMID: 34359784 DOI: 10.3390/cancers13153884] [Reference Citation Analysis]
2 Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE. J Nucl Med 2021;62:1118-25. [PMID: 33443063 DOI: 10.2967/jnumed.120.256255] [Reference Citation Analysis]
3 Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Semin Nucl Med 2021:S0001-2998(21)00090-8. [PMID: 34893320 DOI: 10.1053/j.semnuclmed.2021.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Alsadi R, Djekidel M, Bouhali O, Doherty JO. Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives. Front Phys 2022;10:940677. [DOI: 10.3389/fphy.2022.940677] [Reference Citation Analysis]
5 Vergnaud L, Giraudet AL, Moreau A, Salvadori J, Imperiale A, Baudier T, Badel JN, Sarrut D. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy. EJNMMI Phys 2022;9:37. [PMID: 35575946 DOI: 10.1186/s40658-022-00462-2] [Reference Citation Analysis]